Neurotrope, Inc. (NASDAQ:NTRP) went up to recover about 35.14% since recording its record low price of $3.33. The stock experienced 5.14% jump, arriving at $4.5 on 02/21/2019. During the day, the stock price traveled from $4.26 to $4.75. This company shares are 244.44% off its target price of $15.5 and the current market capitalization stands at $34.65M. The recent change has given its price a 10.17% lead over SMA 50 and -62.27% deficit over its 52-week high. The stock witnessed 14.5% gains, -25.12% declines and -50% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NTRP’s volatility during a week at 5.48% and during a month it has been found around 5.21%.

Neurotrope, Inc. (NTRP) Top Holders

Institutional investors currently hold around $6 million or 28.1% in NTRP stock. Look at its top three institutional owners. Vanguard Group Inc owns $920 thousand in Neurotrope, Inc., which represents roughly 2.66% of the company’s market cap and approximately 15.33% of the institutional ownership. Similar statistics are true for the second largest owner, Tanaka Capital Management Inc, which owns 198,895 shares of the stock are valued at $851 thousand. The third largest holder is Cannell Peter B & Co Inc, which currently holds $806 thousand worth of this stock and that ownership represents nearly 2.33% of its market capitalization.

Neurotrope, Inc. 13F Filings

At the end of December reporting period, 8 institutional holders increased their position in Neurotrope, Inc. (NASDAQ:NTRP) by some 189,043 shares, 10 decreased positions by 239,561 and 12 held positions by 956,662. That puts total institutional holdings at 1,385,266 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 136,651 shares while 3 institutional investors sold out their entire positions totaling 34,844 shares.

Neurotrope, Inc. (NASDAQ:NTRP) Insider Trades

Multiple company employees have indulged in significant insider trading. Neurotrope, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Gottlieb James has sold 314 shares of Neurotrope, Inc. (NTRP) in trading session dated Mar. 15, 2018. These shares are worth $2,644 and were traded at $8.42 each. The SEC filing shows that Bernstein Bruce performed a purchase of 1,563 shares. The Director added these shares by way of transaction on Dec. 02, 2016. The company’s shares were assimilated at $8.96 per share worth to an investment of some $14,004 on account of Bernstein Bruce.

Director, Gorelick Kenneth J, purchased 156 common shares of Neurotrope, Inc. (NTRP) in the open market. In a transaction dated Nov. 23, 2016, the shares were bought at an average price of $9.28, giving away a sum of $1,448. After this purchase, 313 common shares of NTRP are directly owned by the insider, with total stake valued at $1,409.

In the transaction dated Aug. 26, 2016, the great number of shares acquired came courtesy the Director; Gorelick Kenneth J added a total of 156 shares at an average price of $13.12, amounting to approximately $2,047. The insider now directly owns 156 shares worth $702.

Neurotrope, Inc. (NTRP) Analyst Guide

Several analysts have released their opinion on Neurotrope, Inc. (NASDAQ:NTRP), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.